Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approval comes early for Regeneron's Eylea in DME

This article was originally published in Scrip

Executive Summary

US FDA approval was granted three weeks early for the Regeneron Pharmaceuticals vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) in the treatment of diabetic macular edema (DME), broadening the blockbuster biologic's label beyond its first two indications.


Related Content

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts